article thumbnail

Opinion: Shortages of generic drugs can’t be blamed solely on group purchasing organizations

STAT

More than 90% of prescriptions filled that year were for generics or biosimilars, up from just over 18% the year that Hatch-Waxman was passed. The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was one of the most significant cost-reducing policy innovations of the last 40 years.

article thumbnail

Cap on Out-of-Pocket Insulin Costs in Inflation Reduction Act Increased Prescription Fills

Pharmacy Times

Thousands more people filled their insulin prescriptions following the introduction of the cap in January 2023, especially compared to those who were not enrolled in Medicare, a new study finds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Pharmacy Times

The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% in 2013 to 19.3% to 49.9%.

article thumbnail

Giving Priority to Patient Care in Neighborhood Pharmacies

assurecare

This challenge is particularly prevalent in independent community pharmacies, where owners and managers juggle various roles, from prescription filling to team management and clinical services provision.

article thumbnail

Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022

Big Molecule Watch

According to the findings, more than 90% of all prescriptions filled in 2022 were for generic or biosimilar drugs, despite these medications accounting for less than 18% of the total prescription drug expenditure and a mere 2% of the overall U.S. Notably, the U.S. healthcare spending.

article thumbnail

STAT+: Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows

STAT

But health care stocks fell significantly less than other companies as the amount of care received and prescriptions filled returned closer to pre-pandemic norms. By almost every measure, 2022 was a bad year for the stock market.

article thumbnail

Revolutionizing Health Care: The Evolving Path of E-Prescriptions

National Association of Boards of Pharmacy

Further, a lack of interoperability between pharmacy systems can prevent electronic data sharing between competing pharmacies, which can be frustrating for patients, prescribers, and pharmacy staff when prescriptions are sent to the wrong pharmacy or the patient decides to have the prescription filled elsewhere.